+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anxiolytics - Global Strategic Business Report

  • PDF Icon

    Report

  • 78 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5302271
The global market for Anxiolytics was estimated at US$949.2 Million in 2023 and is projected to reach US$1.3 Billion by 2030, growing at a CAGR of 4.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Anxiolytics Market - Key Trends and Drivers Summarized

Why Are Anxiolytics So Crucial in Modern Medicine?

Anxiolytics, commonly referred to as anti-anxiety medications, are a class of psychotropic drugs designed to alleviate symptoms of anxiety, stress, and related disorders by modulating the chemical balance within the brain. The primary mechanism through which anxiolytics work involves influencing neurotransmitters like gamma-aminobutyric acid (GABA), serotonin, and norepinephrine, which play a critical role in regulating mood, stress responses, and overall mental stability. GABA, in particular, is a key inhibitory neurotransmitter that helps reduce neuronal excitability. Anxiolytics such as benzodiazepines - like diazepam and lorazepam - enhance the effect of GABA, thereby inducing a calming effect, reducing excessive brain activity, and providing rapid relief from acute anxiety episodes. Other classes of anxiolytics, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), work by increasing the availability of serotonin or norepinephrine in the brain, which helps stabilize mood and alleviate anxiety over a more extended period. Additionally, newer classes like beta-blockers can be used off-label to manage physical symptoms of anxiety, such as rapid heartbeat and tremors. The pharmacodynamics of each anxiolytic class varies, making them suitable for different types of anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and post-traumatic stress disorder (PTSD). Understanding these nuanced mechanisms is crucial, as the efficacy and safety profiles of these drugs depend significantly on the nature and severity of the anxiety, patient history, and the presence of co-occurring mental health conditions.

Why Are Anxiolytics Increasingly Prescribed Across Various Populations?

The widespread use of anxiolytics is a reflection of the growing prevalence of anxiety disorders and the increasing recognition of mental health issues as critical components of overall health. According to recent statistics from global health organizations, anxiety disorders affect more than 260 million people worldwide, making them one of the most common mental health conditions. This trend has prompted healthcare professionals to incorporate anxiolytics into treatment regimens more frequently, not only for managing chronic anxiety but also for addressing acute stress reactions and co-morbid conditions such as depression and insomnia. The demographic of individuals prescribed anxiolytics is also expanding beyond typical high-stress groups like working adults to include adolescents, older adults, and even children in some cases. For example, the pressures associated with academic performance, social expectations, and the rise of digital stressors have contributed to an increase in anxiety diagnoses among younger populations, leading to greater reliance on SSRIs and SNRIs for longer-term management. On the other end of the age spectrum, elderly patients are increasingly being prescribed anxiolytics to manage anxiety stemming from health concerns, social isolation, or cognitive decline. This broadening demographic is also partly driven by the shifting societal perspective that views mental health treatment as a necessity rather than a stigma. Furthermore, anxiolytics are often prescribed as adjuncts to psychotherapy, enabling patients to engage more effectively in cognitive behavioral therapy (CBT) or other therapeutic interventions by reducing the intensity of anxiety symptoms.

What Are the Recent Advances in Anxiolytic Medications?

Recent developments in anxiolytic pharmacotherapy are focused on enhancing safety, reducing side effects, and addressing the unmet needs in anxiety treatment. A significant innovation is the development of non-benzodiazepine anxiolytics, which aim to provide effective anxiety relief without the sedative and dependency issues associated with traditional benzodiazepines. Drugs like buspirone, which acts as a serotonin receptor agonist, offer a non-sedating alternative for patients with generalized anxiety disorder (GAD) and have a lower risk of abuse. Another advancement is the growing exploration of neurosteroids and glutamate receptor modulators, which target different neurotransmitter systems than conventional anxiolytics. For instance, drugs like brexanolone, a neuroactive steroid, modulate GABA receptors in a unique way, offering new therapeutic avenues for treatment-resistant anxiety and conditions such as postpartum anxiety. Additionally, research is increasingly focused on medications that can address anxiety's cognitive aspects, like rumination and excessive worry, rather than just its somatic symptoms. The introduction of partial serotonin agonists and drugs that influence cannabinoid receptors are also generating interest, as they promise to fine-tune anxiety management without disrupting the broader neurochemical balance. Beyond pharmacological innovations, there is a trend towards personalized medicine, where genetic profiling and biomarkers are used to predict individual responses to anxiolytics, thereby improving treatment outcomes and minimizing side effects. This personalized approach is being complemented by the use of digital therapeutics, where anxiolytics are combined with smartphone-based applications or virtual reality tools that provide real-time monitoring and support, making anxiety management more holistic and patient-centric.

What's Driving the Growth of the Anxiolytic Market?

The growth in the anxiolytic market is driven by several factors, including the rising prevalence of anxiety disorders, greater awareness and acceptance of mental health treatment, and the increasing availability of novel therapeutic options. One of the primary growth drivers is the global rise in anxiety and stress-related conditions, which has been exacerbated by factors such as socio-economic instability, workplace stress, and more recently, the impact of the COVID-19 pandemic. The pandemic has particularly highlighted the need for effective anxiety management, as millions of people have experienced increased stress, isolation, and uncertainty, leading to a surge in demand for both prescription and over-the-counter anxiolytics. In addition, the growing emphasis on mental health by governments and healthcare institutions has led to expanded access to psychiatric care, which includes a broader use of anxiolytics as first-line or adjunct treatments. The development of next-generation anxiolytics with improved safety profiles is also fueling market growth, as these newer medications offer alternatives for patients who are unable to tolerate or are at risk of adverse effects from traditional benzodiazepines. Moreover, the expansion of telemedicine and digital health services has made psychiatric consultations and medication management more accessible, particularly in underserved or remote areas, thereby increasing the overall market reach. Changing consumer attitudes towards mental health treatment are another key factor, as the stigma associated with anxiety disorders diminishes and more people are willing to seek help. Furthermore, the growing trend of polypharmacy in treating complex co-morbid conditions - where anxiolytics are used alongside antidepressants, antipsychotics, or mood stabilizers - has also contributed to rising prescription rates. Lastly, advancements in drug delivery methods, such as extended-release formulations and novel oral dispersible tablets, are enhancing patient adherence and expanding the use of anxiolytics in non-traditional settings, thus creating new growth opportunities for pharmaceutical companies in this sector.

Regional Analysis

Gain insights into the U.S. market, which was estimated at $250.6 Million in 2023, and China, forecasted to grow at an impressive 7.1% CAGR to reach $283.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Anxiolytics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Anxiolytics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Anxiolytics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Anxiolytics market such as Allergan, AstraZeneca, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., Endo International plc and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 12 companies featured in this Anxiolytics market report include:

  • Allergan
  • AstraZeneca
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline
  • Johnson and Johnson
  • Mylan N.V.
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Anxiolytics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Anxiety Disorders Drives Demand for Anxiolytics
  • Growing Awareness of Mental Health Expands Addressable Market for Anxiolytic Medications
  • Increasing Use of Telemedicine Spurs Adoption of Digital Prescriptions for Anxiolytics
  • Advances in Drug Delivery Systems Propel Growth of Fast-Acting Anxiolytics
  • Shifting Preference Towards Non-Benzodiazepine Anxiolytics Throws Spotlight on Safer Alternatives
  • Here`s How the COVID-19 Pandemic Accelerated Demand for Anxiety Management Solutions
  • Integration of AI in Drug Discovery Strengthens Business Case for Next-Generation Anxiolytics
  • Rising Incidence of Stress-Induced Disorders Expands Market Opportunity for Anxiolytics
  • Growing Focus on Personalized Medicine Generates Demand for Tailored Anxiolytic Therapies
  • Advances in Neuroscience Research Drives the Development of Targeted Anxiolytic Therapies
  • Rising Demand for Non-Addictive Anxiolytics Strengthens the Business Case for Safer, Long-Term Solutions
  • Expansion of Online Pharmacies Drives Growth in Global Distribution of Anxiolytics
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Anxiolytics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 5: USA Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 6: USA Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CANADA
  • Table 7: Canada Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 8: Canada Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
JAPAN
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 9: Japan Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 10: Japan Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
CHINA
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 11: China Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 12: China Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
EUROPE
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 13: Europe Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: Europe Historic Review for Anxiolytics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 15: Europe 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 16: France Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 17: France Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
GERMANY
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 18: Germany Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 19: Germany Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ITALY
  • Table 20: Italy Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 21: Italy Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
UNITED KINGDOM
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 22: UK Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 23: UK Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
SPAIN
  • Table 24: Spain Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 25: Spain Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
RUSSIA
  • Table 26: Russia Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: Russia Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF EUROPE
  • Table 28: Rest of Europe Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 29: Rest of Europe Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ASIA-PACIFIC
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 31: Asia-Pacific Historic Review for Anxiolytics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 32: Asia-Pacific 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • Table 33: Australia Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 34: Australia Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
INDIA
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • Table 35: India Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: India Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
SOUTH KOREA
  • Table 37: South Korea Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 38: South Korea Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF ASIA-PACIFIC
  • Table 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 40: Rest of Asia-Pacific Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
LATIN AMERICA
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • Table 41: Latin America Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 42: Latin America Historic Review for Anxiolytics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: Latin America 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
ARGENTINA
  • Table 44: Argentina Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: Argentina Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
BRAZIL
  • Table 46: Brazil Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 47: Brazil Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
MEXICO
  • Table 48: Mexico Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 49: Mexico Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF LATIN AMERICA
  • Table 50: Rest of Latin America Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Rest of Latin America Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
MIDDLE EAST
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • Table 52: Middle East Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 53: Middle East Historic Review for Anxiolytics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 54: Middle East 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
IRAN
  • Table 55: Iran Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 56: Iran Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
ISRAEL
  • Table 57: Israel Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 58: Israel Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
SAUDI ARABIA
  • Table 59: Saudi Arabia Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 60: Saudi Arabia Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
UNITED ARAB EMIRATES
  • Table 61: UAE Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 62: UAE Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
REST OF MIDDLE EAST
  • Table 63: Rest of Middle East Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 64: Rest of Middle East Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
AFRICA
  • Anxiolytics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • Table 65: Africa Recent Past, Current & Future Analysis for Anxiolytics by Segment - Anxiolytics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 66: Africa Historic Review for Anxiolytics by Segment - Anxiolytics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Allergan
  • AstraZeneca
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline
  • Johnson and Johnson
  • Mylan N.V.
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information